Incorporation of the technology will allow Absorption Systems to more precisely identify drug metabolites, while retaining sensitivity and dynamic range, and quantify low-level components in complex biological matrices.
This improves Absorption Systems’ metabolite identification capabilities, which are an important element of its drug metabolism programme. Using the programme helps researchers select the most appropriate nonclinical toxicology species based on exposure to human metabolites.
Patrick Dentinger, president and CEO of Absorption Systems, added: “The LTQ Orbitrap XL provides our clients with superior precision, sensitivity and performance when conducting metabolite ID.”